Sign In
Buy NBIX
$167.35
+2.24 (+1.36%)
At Close: Jun 04, 2026
Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community
08:30am, Wednesday, 24'th Apr 2024
WHAT THE C@H?! provides a platform for the congenital adrenal hyperplasia (CAH) community to find educational information, share experiences and learn about current research.
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
07:00am, Tuesday, 23'rd Apr 2024
SAVITRI™ Study Met Primary Endpoint with Statistically Significant Reduction in Montgomery Åsberg Depression Rating Scale ( MADRS) Total Score at Day 28 Met Key Secondary Endpoints, Including Stati
Three top U.S. biotech stocks to buy in April
09:06am, Thursday, 28'th Mar 2024
“Biotech industry has found its footing again”, says Karen Andersen – a Morningstar strategist. Here are the top U.S. based stocks within this space that are particularly worth owning for 2024.
S&P 500 Giants Lead Five Stocks Near Buy Points With Fed's Powell A Tailwind
08:00am, Saturday, 23'rd Mar 2024
S&P 500 stocks DexCom, Blackstone and Royal Caribbean lead five stocks around buy points after Fed chief Jerome Powell helped buoy markets.
AI Plays HubSpot, Arista Networks Lead Five Stocks Near Buy Points In Classic Base
08:00am, Saturday, 16'th Mar 2024
Artificial intelligence plays HubSpot and Arista Networks are among five stocks near buy points with big market news on tap.
3 Cutting-Edge Biotech Stocks Sitting on the Brink of Success
04:45pm, Wednesday, 06'th Mar 2024
Biotech stocks have always been high-risk and high-reward, with the futures and fortunes of companies often decided with a single successful drug trial or Federal Drug Administration (FDA) approval. T
Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside
08:30pm, Saturday, 10'th Feb 2024
Neurocrine Biosciences' shares have sold off post-earnings on concerns about its near-term opex spending and slowing growth for lead drug Ingrezza. Higher-than-expected opex spending includes targeted
Neurocrine (NBIX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
10:39am, Wednesday, 07'th Feb 2024
While the top- and bottom-line numbers for Neurocrine (NBIX) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics com
AMLX vs. NBIX: Which Stock Should Value Investors Buy Now?
12:40pm, Wednesday, 31'st Jan 2024
Investors with an interest in Medical - Drugs stocks have likely encountered both Amylyx Pharmaceuticals, Inc. (AMLX) and Neurocrine Biosciences (NBIX). But which of these two companies is the best op
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
11:06am, Wednesday, 31'st Jan 2024
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2023 Financial Results
04:16pm, Wednesday, 17'th Jan 2024
Conference Call and Webcast Scheduled for Wednesday, February 7 SAN DIEGO , Jan. 17, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth q
Wedbush's Laura Chico talks biotech investing in 2024
05:21pm, Tuesday, 26'th Dec 2023
Laura Chico, Wedbush Biotech Analyst, joins 'Closing Bell Overtime' to talk investing in biotech.
Neurocrine (NBIX) Soars 6.0%: Is Further Upside Left in the Stock?
09:01am, Tuesday, 26'th Dec 2023
Neurocrine (NBIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
3 Stocks at the Forefront of Medical Innovation
08:23pm, Monday, 25'th Dec 2023
Innovation in the medical world is undoubtedly a fundamental pillar in the development of humanity. There are great companies within the biotech sector doing wonderful work, research, and developments
The 3 Most Undervalued Biotech Stocks to Buy in December
02:30pm, Friday, 15'th Dec 2023
As technology advances in our era, biotechnology is not far behind. Modern day medical advancements are impressive, and the company's making these strides have incredible results to show for it.
